ATP13A2 Antibodies

Santa Cruz Biotechnology provides a broad selection of ATP13A2 monoclonal antibodies for research focused on understanding cellular homeostasis and metal ion transport. ATP13A2 monoclonal antibodies are suitable for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). ATP13A2, also known as PARK9, is a lysosomal ATPase essential for maintaining cellular balance and regulating metal ion movement across membranes. Mutations in ATP13A2 have been identified in several neurodegenerative conditions, emphasizing its importance in preserving neuronal health and function. Research has shown that ATP13A2 dysfunction can lead to impaired lysosomal function and cellular stress. Understanding ATP13A2's role in cellular processes may reveal new approaches for therapeutic intervention in neurodegenerative diseases. Investigating ATP13A2 function continues to yield valuable insights into cellular homeostasis mechanisms. Current studies are exploring how ATP13A2 regulation affects various cellular pathways and disease progression. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of ATP13A2's role in health and disease.